Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn's Disease: A Retrospective, International Multicenter Study.

Robert D LittleAdrian SwaineRebecca ReynoldsDavid J GibsonMathilde BarrauFrancesca D'ErricoRumneek HampalMiles P SparrowXavier RoblinPeter M IrvingMark G Ward

Published in: Inflammatory bowel diseases (2023)

Drug levels following dose-intensification rather than at the time of secondary loss of response were associated with subsequent CD remission.

Keyphrases

rheumatoid arthritis
ulcerative colitis
emergency department
adverse drug
disease activity
drug induced
systemic lupus erythematosus
electronic health record